Medtronic Plc (MDT) experienced robust growth in its Cardiac segment in the Q3 2025 Earnings Call. However, shares fell due to pressure in surgical unit coming Q4. While Medtronic reports higher revenue and adjusted profit, stock slips after revenue fail to meet expectations. Even so, Medtronic still beats profit estimates with innovations in AI-Powered Healthcare and AFib detection contributing to its steady performance. Jim Cramer, market expert, remains bullish on the stock's performance. In spite of a few assets performing under expectation, Medtronic is still among top long-term investment options due to its strong revenue growth and technology-driven advancements in medical therapies. MDT stock is now cheaper than its peers, making it an attractive buy before Q3 earnings. However, downside risk ties to its weak fundamentals. Despite these, Medtronic continues to show strength in diabetes and heart devices driving earnings beat. Medtronic is additionally bolstered by increasing demand for medical devices and is slated as a top pick for Goldman Sachs fund manager.
Medtronic Plc MDT News Analytics from Thu, 23 May 2024 07:00:00 GMT to Wed, 19 Feb 2025 13:10:57 GMT -
Rating 6
- Innovation 7
- Information 7
- Rumor -2
